Johns Hopkins Medicine researchers provided clinical validation supporting the first FDA-cleared rapid urine test to aid diagnosis of invasive aspergillosis. The approach aims to reduce time-to-diagnosis in high-risk patients where early detection is critical for survival. Rapid diagnostics are increasingly important as clinicians manage invasive fungal infections under intensive immunosuppression. A urine-based test could lower reliance on slower sampling workflows or more invasive procedures, particularly in clinical settings that struggle with rapid access to confirmatory assays. For adoption, the key near-term questions will center on performance across patient subgroups, integration into existing diagnostic pathways, and how clinicians use results alongside imaging and microbiology findings.